2024 wird ein starkes Jahr für IPOs, und die hochinnovative Medtech Branche ist gut positioniert, um davon zu profitieren

Anticipating cuts in interest rates as a result of easing inflationary pressures, the financial markets have seen indices such as the S&P 500, DAX and CAC 40 reach record highs. This buoyancy has led to a continuous increase in investor appetite for IPOs. During 2023 and Q1 2024 the largest 15 US and European IPOs successfully raised close to $30 billion. Flagship European life sciences IPOs like Galderma, Schott Pharma and Renk fared especially well, underscoring the market’s interest in this dynamic sector.

We have identified six trends powering that dynamism.

1. Quest for Eternal Life Fuels Expanding Longevity Industry
2. Smart Implants Elevate Post-Surgery Outcomes
3. AI & ML Revolutionize Clinical Trials
4. Structured Data Improves Disease Surveillance
5. Radiopharmaceuticals Market Expected to Grow Significantly
6. Gene Therapy Transforms Treatment of Sickle Cell and Other Diseases

These trends highlight the sector’s readiness for investment and mark life sciences IPOs as a particularly compelling opportunity in 2024.

> Download the full report here